Home Daily Intelligence Tracker
    • Plans Blog Contact
    Bausch & Lomb Corp logo
    BLCO

    Bausch & Lomb Corp

    MaveScore 24 Low model confidence
    Last Price US$16.23 As of Jul 10, 2026
    Market Cap US$5.8b Company size context
    7D Performance -5.42% Past 7 days
    1Y Performance 14.38% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 24 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    9/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    6/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    5/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    4/15 Weak

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Bausch & Lomb Corp Overview

    Industry: Medical Instruments & Supplies

    Sector: Healthcare

    Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc. Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently re Read More

    Bausch & Lomb Corp is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Bausch & Lomb Corp

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 29, 2026

    Quarterly result summary

    Revenue was $1.2B (+9% YoY); EPS was $ (reported).

    Revenue $1.2B +9% YoY
    EPS $ reported
    Operating income $33M reported
    Net loss -$70 reported

    What changed

    • Revenue +9% YoY to $1.2B; EPS reported to $.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Apr 29, 2026 SEC filing 8-K Apr 29, 2026 SEC filing 10-K Feb 18, 2026 SEC filing 8-K Feb 18, 2026 Earnings release Earnings release Feb 18, 2026 Earnings release Earnings release Oct 29, 2025 SEC filing 10-Q Oct 29, 2025 SEC filing 8-K Oct 29, 2025 Earnings release Earnings release Jul 30, 2025 SEC filing 8-K Jul 30, 2025 SEC filing 10-Q Jul 30, 2025

    Recent News



    Bausch + Lomb Explores Potential Sale in Strategic Move Towards Independence
    1 hour ago
    Bausch + Lomb down after report that Blackstone could back away from takeover bid
    12 hours ago
    Bausch + Lomb Expands Glaucoma Treatment Portfolio
    22 hours ago

    Earnings Per Share

    Score 1.00/5
    Bausch & Lomb Corp earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Return on Equity

    Score 2.23/5
    Bausch & Lomb Corp exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Bausch & Lom... BLCO US$5.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.37/5
    Bausch & Lomb Corp olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Bausch & Lom... BLCO US$5.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Leverage

    Score 2.25/5
    Bausch & Lomb Corp registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Bausch & Lom... BLCO US$5.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Bausch & Lomb Corp logo

    Bausch & Lomb Corp

    US$16.23

    US$5.8b

    -5.42%

    14.38%